Biktarvy: adverse event reports filed with FDA

6,739

reports as suspect product

0% of all reports · about 426 a year

677

reports, 12 months to June 2026

791 in the 12 months before

54.7%

marked serious by the reporter

84.3% across the class

8.2%

record death among outcomes, as reported

551 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Biktarvy reports recording the termmedian drug in human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor

1. Weight increasedweight gain6.3%427
2. Deaththe patient died; cause not stated by this term5.5%368
3. Product storage errorthe product was stored wrongly3%205
4. Nauseafeeling sick2.9%198
5. Drug ineffectivethe medicine did not work as expected2.9%194
6. Headachehead pain2.8%189
7. Fatiguetiredness2.7%183
8. Rashskin rash2.6%177
9. Diarrhoealoose or frequent stools2.6%174
10. Viral load increased2.5%167
11. Maternal exposure during pregnancythe mother took the medicine during pregnancy2.4%163
12. Product dose omission issuea dose was missed2.3%155
13. Off label useused for a purpose or in a way not on the label2.2%151
14. Vomitingbeing sick2.1%144
15. Insomniadifficulty sleeping1.9%128
16. Immune reconstitution inflammatory syndrome1.7%117
17. Product dispensing error1.5%103
18. Treatment noncompliancethe treatment was not taken as directed1.5%101
19. Dizzinesslight-headedness or unsteadiness1.5%100
20. Arthralgiajoint pain1.4%92
21. Drug interactionan interaction between medicines1.4%92
22. Pyrexiafever1.3%90
23. Dysphagiadifficulty swallowing1.3%89
24. Anxietyanxiety1.2%84
25. Depressionlow mood1.2%83
26. Drug resistance1.2%82
27. Dyspnoeashortness of breath1.2%81
28. Hospitalisationadmission to hospital1.2%81
29. Blood HIV RNA increased1.2%80
30. Product use issuea problem in how the product was used1.2%80

Top 30 of 842 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 13 drugs in the human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 80,988 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 69% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 6,739 reports.

Drugs most often listed in the same reports

Other products listed in reports where Biktarvy is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Biktarvy as a suspect or interacting product; reports listing it only as a concomitant medication (11,284) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.